Olaparib and High-Dose Chemotherapy in Treating Patients with Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
- Patients with: * Diffuse large B-cell lymphoma (DLBCL) with one of the following: ** Primary refractory (no CR to 1st line) ** High-risk relapse, defined as any of the following: first complete remission (CR1) < 6 months [mo], secondary International Prognostic Index [IPI] > 1, or lactate dehydrogenase [LDH] > 225 U/L. ** Refractory relapse: No response to >= 1 salvage line and not eligible to receive other novel salvage therapies, such as chimeric antigen receptor T-cells (CAR-T) in a timely fashion or have already failed these. * Hodgkin’s with one of the following: ** Primary refractory (no CR or progressive disease [PD] within 3 months) ** High-risk relapse, defined as any of the following: CR1 < 1 year, extranodal relapse, or B symptoms. ** Refractory relapse: No response to >= 1 salvage line * T-non Hodgkin's lymphoma (T-NHL) with one of the following: ** Primary refractory (no CR to 1st line) ** High-risk relapse (within 6 months) ** Refractory relapse to >= 1 line of salvage ** Any other lymphoma that is refractory or relapsed and that does not qualify for autologous transplant protocols of higher priority.
- Creatinine clearance estimated using the Cockcroft-Gault equation of >= 51 mL/min.
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be =< 5 x ULN.
- Total bilirubin =< 2 x ULN or =< 3 x ULN if Gilbert's disease).
- Forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and carbon monoxide diffusing capacity (DLCOc) >= 50% of predicted.
- Left ventricular ejection fraction (LVEF) >= 40%, no uncontrolled arrhythmias or symptomatic cardiac disease.
- Eastern Cooperative Oncology Group (ECOG) performance status < 2.
- Provision of informed consent prior to any study specific procedures.
- Patients must have a life expectancy >= 16 weeks.
- Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days and within 72 hours of study treatment and confirmed prior to receiving treatment on this study. Patients with positive results will be removed from the study. Postmenopausal is defined as one of the following: * Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments. * Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the postmenopausal range for women under 50. * Radiation-induced oophorectomy with last menses > 1 year ago. * Chemotherapy-induced menopause with > 1 year interval since last menses. * Surgical sterilization (bilateral oophorectomy or hysterectomy). * Female patients must agree to use a highly effective birth control method while on study and for at least 1 month after the last dose of study drug(s).
- Male patients and their partners, who are sexually active and of childbearing potential, must agree to the use of two highly effective forms of contraception in combination, throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partner.
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
- Prior apheresis of >= 3 million CD34+ cells/Kg.
- Eligibility for ASCT is determined by the above inclusion criteria.
- Persistent toxicities (> Common Terminology Criteria for Adverse Events [CTCAE] grade 2) caused by previous cancer therapy, excluding alopecia.
- Prior whole brain irradiation.
- Active hepatitis B, either active carrier (hepatitis B surface antigen [HBsAg] +) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >/= 10,000 copies/mL, or >= 2,000 IU/mL).
- Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology.
- Active infection requiring parenteral antibiotics.
- Patients who are known to be serologically positive for human immunodeficiency virus (HIV).
- Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment.
- Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), stage 1, grade 1 endometrial carcinoma, or other solid tumors.
- Resting electrocardiography (ECG) with correct QT interval (QTc) > 470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.
- Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks.
- Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John’s wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
- Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML).
- Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days.
- Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
- Uncontrolled non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent.
- Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
- Breast feeding women.
- Patients with a known hypersensitivity to olaparib or any of the excipients of the product.
I. Establish the maximum tolerated dose (MTD) of olaparib combined with vorinostat/gemcitabine/busulfan/melphalan with autologous stem-cell transplant [ASCT]).
I. Determine the 2-year event-free survival (EFS).
II. Assess 2-year overall survival (OS).
III. Determine complete remission (CR) rate.
IV. Determine overall remission rate (ORR).
V. Describe the toxicity profile.
VI. Describe changes of deoxyribonucleic acid (DNA) damage response and repair, poly(ADP-ribose) polymerase (PARP) inhibition and downstream cellular effects in peripheral blood mononuclear cells and, when available, malignant lymphocytes obtained by fine needle aspiration (FNA) of peripheral lymph nodes.
OUTLINE: This is a dose-escalation study of olaparib.
Patients receive olaparib orally (PO) twice daily (BID) on days -11 to -3, vorinostat PO on days -10 to -3, gemcitabine intravenously (IV) over 4.5 hours on days -9 and -4, busulfan IV over 3 hours on day -9 to -6, melphalan IV over 30 minutes on days -4 and -3, and undergo peripheral blood stem cell transplant IV over 30-60 minutes on day 0. Patients with CD20+ tumors also receive rituximab IV over 3-6 hours on day -10.
After completion of study treatment, patients are followed up every 1-2 days for 30 days and then every 2 weeks for up to 100 days.
Trial Phase Phase I
Trial Type Treatment
M D Anderson Cancer Center
Yago L. Nieto
- Primary ID 2017-0073
- Secondary IDs NCI-2018-01094
- Clinicaltrials.gov ID NCT03259503